None Better than One? (A Brief Note on VC in Smaller Hubs)
Biotech venture funding metrics continue at historic highs, highlighting that the robust financing environment…
venture capital
There are 20 articles under this tag
What is the optimal biotech burn rate?
Ethan Perlstein, founder of Perlstein Lab, asked a question on Twitter and got some great…
Could Pharma/Biotech Build an Amazon?
Pharma/Biotech Business Model Innovation When I hear/read about business model innovation in pharma/biotech, the themes…
Biotech: Outside Looking In
In a post in March, I suggested that I would represent the "less glamorous…
(Re)Reading This Weekend (6/14/14)
There were a few long reads that I'll be re-reading over the weekend, including: New…
Risk Distribution & Opportunity Costs in Entrepreneurship
Risk Distribution In WIRED, "One Startup’s Struggle to Survive the Silicon Valley Gold Rush"…
Is Biotech Venture Capital Dying?
This post was inspired by the Xconomy story Wisconsin 2013 VC Activity Drops, Shifts…
Early Stage Biotech Investing in Wisconsin: Hot or Not?
In this post, I want to look at funding, particularly via angel investing, of…
WI VC Investment: Down (& Out?) in Q3 ’13
The venture capital investment numbers are out for the Q3 2013 (courtesy of NVCA & PwC). I am usually…
Engineering Capital Flow: Thoughts on Wisconsin & Beyond
Late last month there was a formal announcement of a new $30 million information…
Load More